GPC5

Across TCGA pan-cancer cohorts, GPC5 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated GPC5 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher GPC5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GPC5 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

STAD, LIHC, and UCEC are the cancer types where GPC5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.222	0.594	<.001	42	view →
LIHC	OS	Median	All	0.051	0.783	<.001	36	view →
UCEC	DFS	Median	II,III,IV	0.941	0.428	.007	30	view →
MESO	OS	Median	II,III,IV	0.071	0.572	<.001	24	view →
CESC	OS	Median	III,IV	0.091	0.755	<.001	24	view →
COAD	OS	Median	II,III,IV	0.464	0.853	<.001	19	view →
SKCM	DFS	Median	II,III,IV	0.767	0.528	.011	7	view →
PRAD	DFS	Median	All	0.096	0.935	<.001	6	view →
BLCA	DFS	Median	III,IV	0.266	0.554	.024	6	view →
ESCA	OS	Median	All	0.328	0.703	.027	6	view →
SARC	DFS	Median	All	0.179	0.594	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

GPC5–STAD (OS)

Open the STAD breakdown →